ストックスクリーナーアプリを入手
3.25
15.14%
-0.58
アフターアワーズ：
3.20
-0.05
-1.54%
Savara Inc (SVRA) 最新ニュース
SVRA stock touches 52-week low at $3.27 amid market challenges - Investing.com
Evercore Downgrades Savara on Manufacturing Concerns for Lung Di - GuruFocus.com
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate - Yahoo Finance
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate - Seeking Alpha
Savara (NASDAQ:SVRA) Earns "In-Line" Rating from Evercore ISI - MarketBeat
Savara (SVRA) to Present at Jefferies and Piper Sandler Healthcare Conferences | SVRA Stock News - StockTitan
Jennison Associates LLC's Strategic Acquisition of Savara Inc Sh - GuruFocus.com
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
Savara Inc. Grants Inducement Awards to New Chief Commercial Officer - MSN
Piper Sandler keeps Overweight rating on Savara shares - Investing.com
FY2025 EPS Estimates for Savara Inc (NASDAQ:SVRA) Reduced by HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Trading Down 3.5% - MarketBeat
Savara maintains buy stock rating on aPAP drug potential By Investing.com - Investing.com Australia
Savara maintains buy stock rating on aPAP drug potential - Investing.com
JMP Securities Reiterates “Market Outperform” Rating for Savara (NASDAQ:SVRA) - Defense World
Will Savara Inc (SVRA) beat or miss earnings estimates this quarter? - US Post News
Metric Analysis: Savara Inc (SVRA)’s Key Ratios in the Limelight - The Dwinnex
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting - StockTitan
JMP Securities Reaffirms "Market Outperform" Rating for Savara (NASDAQ:SVRA) - MarketBeat
Savara Inc (NASDAQ:SVRA) Stock Position Increased by XTX Topco Ltd - Defense World
Savara Inc (NASDAQ:SVRA) is Nantahala Capital Management LLC's 9th Largest Position - MarketBeat
Savara shares hold Outperform rating, $15 target on Molbreevi prospects By Investing.com - Investing.com Australia
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock - Investing.com
Savara shares hold Outperform rating, $15 target on Molbreevi prospects - Investing.com India
Savara Inc. Appoints Braden Parker as Chief Commercial Officer - MSN
What is Savara Inc (SVRA) Stock Return on Shareholders’ Capital? - SETE News
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock By Investing.com - Investing.com Canada
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Frazier Life Sciences Management L.P. Buys 4,157,385 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
6.21%
0.93%
大文字化:
|
ボリューム (24 時間):